TFO Wealth Partners LLC Has $51,000 Stock Position in Haemonetics Co. (NYSE:HAE)

TFO Wealth Partners LLC grew its holdings in Haemonetics Co. (NYSE:HAEFree Report) by 29,450.0% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 591 shares of the medical instruments supplier’s stock after purchasing an additional 589 shares during the period. TFO Wealth Partners LLC’s holdings in Haemonetics were worth $51,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in HAE. Group One Trading L.P. acquired a new position in Haemonetics during the third quarter valued at approximately $55,000. Parkside Financial Bank & Trust grew its stake in shares of Haemonetics by 17.4% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,054 shares of the medical instruments supplier’s stock valued at $90,000 after buying an additional 156 shares in the last quarter. C M Bidwell & Associates Ltd. grew its stake in shares of Haemonetics by 19.7% in the third quarter. C M Bidwell & Associates Ltd. now owns 2,389 shares of the medical instruments supplier’s stock valued at $214,000 after buying an additional 393 shares in the last quarter. DekaBank Deutsche Girozentrale raised its position in Haemonetics by 172.8% during the third quarter. DekaBank Deutsche Girozentrale now owns 2,657 shares of the medical instruments supplier’s stock worth $239,000 after acquiring an additional 1,683 shares in the last quarter. Finally, LVZ Inc. lifted its stake in Haemonetics by 9.4% in the fourth quarter. LVZ Inc. now owns 3,006 shares of the medical instruments supplier’s stock valued at $257,000 after acquiring an additional 259 shares during the last quarter. Institutional investors own 99.67% of the company’s stock.

Insider Activity at Haemonetics

In other Haemonetics news, EVP Michelle L. Basil sold 12,990 shares of the firm’s stock in a transaction dated Wednesday, May 29th. The shares were sold at an average price of $88.08, for a total value of $1,144,159.20. Following the transaction, the executive vice president now directly owns 31,257 shares of the company’s stock, valued at approximately $2,753,116.56. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other news, EVP Michelle L. Basil sold 12,990 shares of the company’s stock in a transaction that occurred on Wednesday, May 29th. The shares were sold at an average price of $88.08, for a total transaction of $1,144,159.20. Following the completion of the sale, the executive vice president now owns 31,257 shares of the company’s stock, valued at approximately $2,753,116.56. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Stewart W. Strong sold 733 shares of the business’s stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $96.04, for a total transaction of $70,397.32. Following the transaction, the insider now owns 15,608 shares of the company’s stock, valued at $1,498,992.32. The disclosure for this sale can be found here. Insiders sold a total of 27,380 shares of company stock valued at $2,445,816 over the last quarter. 1.79% of the stock is owned by corporate insiders.

Haemonetics Stock Down 1.7 %

Shares of HAE opened at $87.37 on Friday. The company has a current ratio of 2.56, a quick ratio of 1.50 and a debt-to-equity ratio of 0.83. Haemonetics Co. has a 12 month low of $70.74 and a 12 month high of $97.97. The firm’s 50 day moving average is $88.90 and its 200-day moving average is $83.45. The stock has a market capitalization of $4.44 billion, a PE ratio of 38.15, a P/E/G ratio of 1.61 and a beta of 0.37.

Haemonetics (NYSE:HAEGet Free Report) last posted its quarterly earnings data on Thursday, May 9th. The medical instruments supplier reported $0.90 EPS for the quarter, topping analysts’ consensus estimates of $0.88 by $0.02. The firm had revenue of $343.00 million for the quarter, compared to analyst estimates of $329.53 million. Haemonetics had a return on equity of 22.25% and a net margin of 8.98%. The company’s revenue was up 12.7% on a year-over-year basis. During the same quarter last year, the company earned $0.77 EPS. Equities research analysts forecast that Haemonetics Co. will post 4.55 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. JMP Securities boosted their price objective on shares of Haemonetics from $115.00 to $125.00 and gave the stock a “market outperform” rating in a research note on Friday, May 10th. TheStreet cut Haemonetics from a “b-” rating to a “c+” rating in a research report on Thursday, February 29th. Barrington Research lifted their target price on Haemonetics from $105.00 to $107.00 and gave the stock an “outperform” rating in a research note on Friday, May 10th. StockNews.com cut Haemonetics from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Haemonetics in a research report on Friday, May 10th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $108.67.

Get Our Latest Stock Analysis on HAE

Haemonetics Company Profile

(Free Report)

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.

Featured Stories

Institutional Ownership by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.